Comparative Pharmacology
Head-to-head clinical analysis: NORTRIPTYLINE HYDROCHLORIDE versus PRESAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTRIPTYLINE HYDROCHLORIDE versus PRESAMINE.
NORTRIPTYLINE HYDROCHLORIDE vs PRESAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminic, and alpha-adrenergic blocking properties.
Predominantly inhibits serotonin reuptake in the presynaptic neuron, increasing serotonin availability in the synaptic cleft. Also inhibits norepinephrine reuptake to a lesser extent.
25 mg orally three times daily or 75 mg orally once daily at bedtime; initial dose 25 mg at bedtime, titrate up to 75-150 mg/day.
100-300 mg/day orally in divided doses, typically starting at 75 mg/day and titrating upward. Maximum dose 300 mg/day.
None Documented
None Documented
Terminal elimination half-life 18-56 hours (mean 28 hours); steady-state reached in 5-7 days.
21 hours (range 16-28 h) for imipramine; active metabolite desipramine ~24 h; clinically, steady-state reached in 5-7 days.
Primarily renal (70% as metabolites, <5% unchanged) and fecal (30% via biliary elimination).
Primarily renal (70% as metabolites, <5% unchanged); biliary/fecal (30%).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant